(Q38460201)

3 September 2017

1 reference

title

Present status of human papillomavirus vaccine development and implementation (English)

1 reference

3 September 2017

1 reference

3

Lauri E Markowitz

1 reference

3 September 2017

Rolando Herrero

1

1 reference

PubMed ID

25943065

3 September 2017

Paula González

series ordinal

2

1 reference

3 September 2017

1 May 2015

1 reference

Lancet Oncology Commission

3 September 2017

1 reference

3 September 2017

16

1 reference

3 September 2017

5

1 reference

3 September 2017

e206-16

1 reference

Global causes of maternal death: a WHO systematic analysis

3 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Global burden of human papillomavirus and related diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

A review of clinical trials of human papillomavirus prophylactic vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Clinical trials of human papillomavirus vaccines and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

HPV vaccine against anal HPV infection and anal intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Four-Year Follow-up of the Immunogenicity and Safety of the HPV-16/18 AS04-Adjuvanted Vaccine When Administered to Adolescent Girls Aged 10–14 Years

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Safety of human papillomavirus vaccines: a review.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Safety of quadrivalent human papillomavirus vaccine administered routinely to females

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Human papillomavirus vaccine introduction--the first five years

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Achieving high and equitable coverage of adolescent HPV vaccine in Scotland.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Achieving high coverage in Rwanda's national human papillomavirus vaccination programme

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Population impact of HPV vaccines: summary of early evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Fall in Human Papillomavirus Prevalence Following a National Vaccination Program

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany-an ecologic study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970481-4

7 January 2021

10.1016/S1470-2045(14)70481-4

Identifiers

DOI

1 reference

3 September 2017

1 reference

PubMed ID

25943065